ClinicalTrials.gg
Active, not recruitingNCT06237257Updated Dec 24, 2024

A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical Cancer

A Phase 2 interventional study of SHR-1316 and Cisplatin Injection/Carboplatin Injection in Locally Advanced Cervical Cancer, sponsored by Shanghai Shengdi Pharmaceutical Co., Ltd. Active, not recruiting at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-12-24.

Sponsored by Shanghai Shengdi Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
56
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 455 studies in Uterine Cervical Neoplasms with a site in China — 205 open to participants now, 240 under way, 35 of them phase 3. Uterine Cervical Neoplasms · China.

Enrollment
207th of 360
56 · median 90
Started
2024
with 60 others
Phase 2
137 of 455
71 open now
Primary completion
2024-12
later than 42 of 239 live
Registered
322nd of 455
by date

Among the 455 studies in Uterine Cervical Neoplasms with a site in China, this one is the 207th largest by enrollment of the 360 interventional ones that give a count, is one of 61 that started in 2024, is one of 137 in phase 2, reaches primary completion later than 42 of the 239 other live ones, and was the 322nd registered.

Uterine Cervical Neoplasms

2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 677 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

205 of the 455 studies in Uterine Cervical Neoplasms with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 474 Uterine Cervical Neoplasms studies recruiting now, 243 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 69 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 455 studies in Uterine Cervical Neoplasms with a site in China, or all of them as a file.
02

Study summary

The Primary purpose of this study is to evaluate the safety of SHR-1316 plus concurrent chemoradiotherapy in participants with locally advanced cervical cancer.

The second purpose of this study is to evaluate the efficacy and PK traits; The exploratory study is to explore the biomarker 、immunogenicity and so on .

03

Conditions studied

  • Locally Advanced Cervical Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide a written
  2. Has -confirmed squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix;
  3. Has locally advanced cervical cancer;
  4. At least one ( version 1.1);
  5. Investigator assess it is suitable for concurrent chemoradiotherapy;
  6. Has provided a tissue sample from tumor lesion;
  7. Cooperative Oncology Group () performance status of 0 or 1;
  8. ≥18.5kg/m2;
  9. Female participants of must agree to use highly effective during the treatment period and for at least 7 months after the last dose of drug,Female participants' HCG must be negative within 3 days prior to enrollment and must be non-lactating.

Exclusion criteria

Exclusion Criteria:

  1. Histopathologically confirmed small cell carcinoma (neuroendocrine) or mucinous adenocarcinoma of the cervix;
  2. The presence of distant disease was confirmed by pathology or imaging;
  3. has previously undergone hysterectomy (including subtotal hysterectomy) or plan to undergo hysterectomy for cervical cancer, or plan to adopt fertility preservation therapy;
  4. In the investigator's judgment, there is a disease (such as severe diabetes, neurological or psychiatric illness, etc.) or any other condition that seriously endangers the subject's safety, confuses the study results, or interferes with the subject's ability to complete the study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    SHR-1316 plus concurrent chemoradiotherapy

    Biological: SHR-1316 · Drug: Cisplatin Injection/Carboplatin Injection · Radiation: External Beam Radiotherapy (EBRT)/Brachytherapy · Drug: Paclitaxel Injection

Interventions

  • BiologicalSHR-1316

    SHR-1316(Adebrelimab Injection)

  • DrugCisplatin Injection/Carboplatin Injection

    Drug pages: Cisplatin · Carboplatin

    Cisplatin Injection/Carboplatin Injection

  • RadiationExternal Beam Radiotherapy (EBRT)/Brachytherapy

    External Beam Radiotherapy (EBRT)/Brachytherapy

  • Paclitaxel Injection.

06

What researchers measure

Primary outcomes

  1. Type, incidence and grade of drug-related adverse events of grade 3 and above

    Time frame: Up to approximately 24 months

Secondary outcomes

  1. Adverse events (AEs) include incidence, grade (judged according to NCI-CTCAE V5.0 standards), duration and correlation with study drugs

    Time frame: Up to approximately 30 months

  2. Rate of Suspension and Discontinuation Due to an Adverse Event correlation with study drug

    Time frame: Up to approximately 30 months

  3. Objective Response Rate(ORR)

    judged based on RECIST 1.1 criteria according to Investigator's assessment

    Time frame: Up to approximately 60 months

  4. Duration of response (DoR)

    judged based on RECIST 1.1 criteria according to Investigator's assessment

    Time frame: Up to approximately 60 months

  5. Progression free survival (PFS)

    judged based on RECIST 1.1 criteria according to Investigator's assessment

    Time frame: Up to approximately 60 months

  6. Overall Survival (OS)

    judged based on RECIST 1.1 criteria according to Investigator's assessment

    Time frame: Up to approximately 60 months

  7. 2-year Progression free survival

    judged based on RECIST 1.1 criteria according to Investigator's assessment

    Time frame: Up to approximately 24 months

  8. 3-year Overall Survival

    judged based on RECIST 1.1 criteria according to Investigator's assessment

    Time frame: Up to approximately 36 months

  9. 12-week Complete Response

    judged based on RECIST 1.1 criteria according to Investigator's assessment

    Time frame: Up to approximately 4 months

  10. PK traits of SHR-1316: Cmax

    Time frame: Up to approximately 24 months

  11. PK traits of SHR-1316: Tmax

    Time frame: Up to approximately 24 months

  12. PK traits of SHR-1316: AUC0-t

    Time frame: Up to approximately 24 months

  13. PK traits of SHR-1316: AUC0-∞

    Time frame: Up to approximately 24 months

  14. PK traits of SHR-1316: t1/2

    Time frame: Up to approximately 24 months

  15. PK traits of SHR-1316: CL

    Time frame: Up to approximately 24 months

  16. PK traits of SHR-1316: Vss

    Time frame: Up to approximately 24 months

  17. Serum concentration of SHR-1316 at each planned blood collection time point

    Time frame: Up to approximately 24 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Dec 2024, 9 months after the start.

Of 50 industry-sponsored phase 2 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 46. This study's planned 9 months is below that.

Counting every sponsor, half of 204 studies reached it within 42 months; a quarter within 29 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2024
First posted
Feb 1, 2024
StartActual
Mar 20, 2024
Primary completionEst.
Dec 2024
CompletionEst.
Jan 2025
Last update
Dec 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06237257
Responsible party
Sponsor
First posted
Feb 1, 2024
Start date
Mar 20, 2024
Primary completion
Dec 2024 (estimated)
Completion
Jan 2025 (estimated)
Last update
Dec 24, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adebrelimab

Start the discussion